We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.
Chinese Clinical Oncology 2017 June
The role of radiation therapy for pancreatic cancer is rapidly evolving in every stage of this disease. In resectable disease, there is conflicting evidence for adjuvant therapy, but an ongoing randomized cooperative group trial is attempting to define the role of adjuvant chemoradiation with modern systemic therapies and radiation techniques with an emphasis on radiation quality assurance. In borderline resectable pancreatic cancer (BRPC), there is an emerging body of literature demonstrating the success of neoadjuvant stereotactic body radiation therapy (SBRT) and a randomized cooperative group trial is actively accruing. For locally advanced pancreatic cancer (LAPC), the recent publication of the LAP07 trial has called into question the role of conventional chemoradiation, but there is a growing experience utilizing SBRT for this patient group. Finally, in the era of immuno-oncology, there may be a new role for radiation therapy in combination with systemic immune therapy to stimulate antigen release and abscopal responses, thus benefitting even patients with metastatic pancreatic cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app